Promising immunotherapies have been developed for cancer: ipilimumab (CTLA-4 antibody) for melanoma [51] and PD-1 and PD-L1 antibody for melanoma, renal cell carcinoma, and lung cancer [52, 53]. Here, CD274 is linked to renal cell carcinoma.